MRTIS TechBio (Beijing) Co., Ltd., a company specializing in artificial intelligence-based nanomedicine, has received permission from the China Securities Regulatory Commission (CSRC) to list overseas in Hong Kong.
According to the company's plans, it intends to issue up to 273 million shares. Additionally, 39 existing shareholders will convert approximately 852 million domestic shares into tradable H-shares as part of a full circulation scheme.
MRTIS was founded in 2020 by Dr. Hongmin Chen, a member of the National Academy of Engineering of the United States, along with scientists from the Massachusetts Institute of Technology (MIT), Kaidan Lai and Wenshou Wang. MRTIS's main focus is innovation in nanomaterials using AI.
The company's proprietary NanoForge platform supports the large-scale development of lipid nanoparticles (LNPs), featuring a database containing tens of millions of compounds. This platform enables targeted delivery to eight key organs and tissues, including the liver, lungs, and immune cells.
The company's lead candidate, MTS-004, is the first AI-developed drug in China to complete Phase III trials. Another candidate, MTS-105, has received orphan drug status from the U.S. Food and Drug Administration (U.S. FDA) and is being developed as a potential first-line therapy based on mRNA-encoded TCE for solid tumors.
The company has raised over $350 million (approximately 2.5 billion yuan) from investors, including XtalPi, HSG, 5Y Capital, and China Life.
